# A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

> **NCT06961721** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Changchun BCHT Biotechnology Co.** · enrollment: 600 (estimated)

## Conditions studied

- Prevention of Herpes Zoster

## Interventions

- **BIOLOGICAL:** Herpes Zoster Vaccine, Live
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06961721
- **Lead sponsor:** Changchun BCHT Biotechnology Co.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2025-07
- **Final completion:** 2025-12
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-05-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06961721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06961721, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06961721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*